Last reviewed · How we verify
C-1-esterase
At a glance
| Generic name | C-1-esterase |
|---|---|
| Also known as | low dose intervention, high dose intervention |
| Sponsor | Penn State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (PHASE2)
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (PHASE3)
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection (PHASE2)
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation (PHASE2)
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) (PHASE2)
- Berinert (C1INH) vs Placebo for DGF/IRI (PHASE1, PHASE2)
- Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) (PHASE4)
- Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C-1-esterase CI brief — competitive landscape report
- C-1-esterase updates RSS · CI watch RSS
- Penn State University portfolio CI